Salmonella typhi Ty21a expressing Yersinia pestis F1-V fusion protein and uses thereof

US9409956B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9409956-B2
Application numberUS-201314402457-A
CountryUS
Kind codeB2
Filing dateMay 22, 2013
Priority dateMay 23, 2012
Publication dateAug 9, 2016
Grant dateAug 9, 2016

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Described herein is the generation of a plasmid construct for expression of a Yersinia pestis F1-V fusion protein. In the disclosed plasmid, the F1-V fusion protein coding sequence is operably linked to the E. coli htrA promoter, and is fused in-frame to the E. coli HlyA secretion signal sequence. Also described is Salmonella enterica serovar Typhi strain Ty21a containing the F1-V fusion protein expression plasmid, such as for use as an oral vaccine against plague.

First claim

Opening claim text (preview).

The invention claimed is: 1. A recombinant nucleic acid molecule comprising a Y. pestis F1-V fusion protein coding sequence operably linked to an E. coli htrA promoter sequence, and further comprising an E. coli HlyA secretion signal peptide secretion signal peptide coding sequence fused in-frame with the F1-V fusion protein coding sequence, wherein the sequence of the nucleic acid molecule comprises SEQ ID NO: 1. 2. A plasmid comprising the recombinant nucleic acid molecule of claim 1 , an origin of replication, a selectable marker and the E. coli HlyB and HlyD protein coding sequences. 3. A plasmid comprising the recombinant nucleic acid molecule of claim 1 . 4. A recombinant nucleic acid molecule comprising a Yersinia pestis F1-V fusion protein coding sequence operably linked to an Escherichia coli htrA promoter sequence, wherein the nucleic acid molecule comprises a sequence at least 95% identical to nucleotides 1-1558 of SEQ ID NO: 1. 5. The recombinant nucleic acid molecule of claim 4 , wherein the nucleic acid molecule comprises the sequence of nucleotides 1-1558 of SEQ ID NO: 1. 6. The recombinant nucleic acid molecule of claim 4 , further comprising a secretion signal peptide coding sequence fused in-frame with the F1-V fusion protein coding sequence. 7. The recombinant nucleic acid molecule of claim 6 , wherein the secretion signal peptide is the E. coli HlyA secretion signal peptide. 8. The recombinant nucleic acid molecule of claim 6 , wherein the sequence of the nucleic acid molecule is at least 95% identical to SEQ ID NO: 1. 9. A plasmid comprising the recombinant nucleic acid molecule of claim 4 . 10. The plasmid of claim 9 , wherein the plasmid is a low-copy number plasmid. 11. The plasmid of claim 9 , further comprising a selectable marker. 12. The plasmid of claim 11 , wherein the selectable marker is an antibiotic resistance gene. 13. The plasmid of claim 9 , further comprising the E. coli HlyB and HlyD protein coding sequences. 14. A Salmonella Typhi Ty21a bacterium comprising the recombinant nucleic acid molecule of claim 4 . 15. An immunogenic composition comprising the Salmonella Typhi Ty21a bacterium of claim 14 and a pharmaceutically acceptable carrier. 16. The immunogenic composition of claim 15 , wherein the composition is formulated for oral administration. 17. A method of eliciting an immune response against Yersinia pestis in a subject, comprising administering to the subject the Salmonella Typhi Ty21a bacterium of claim 14 . 18. The method of claim 17 , wherein the immune response is a protective immune response. 19. A method of reducing the risk of developing plague or treating plague in a subject, comprising administering to the subject the Salmonella Typhi Ty21a of claim 14 .

Assignees

Inventors

Classifications

  • Yersinia · CPC title

  • containing a tag for immunodetection, or an epitope for immunisation · CPC title

  • targeting to the medium outside of the cell, e.g. type III secretion · CPC title

  • expressing foreign proteins · CPC title

  • C07K14/24Primary

    from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9409956B2 cover?
Described herein is the generation of a plasmid construct for expression of a Yersinia pestis F1-V fusion protein. In the disclosed plasmid, the F1-V fusion protein coding sequence is operably linked to the E. coli htrA promoter, and is fused in-frame to the E. coli HlyA secretion signal sequence. Also described is Salmonella enterica serovar Typhi strain Ty21a containing the F1-V fusio…
Who is the assignee on this patent?
Us Health
What technology area does this patent fall under?
Primary CPC classification C07K14/24. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Aug 09 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).